BeOne Medicines Ltd. (ONC) - Q2 2026 10-Q Summary
Business Context and Reporting Period
Company: BeOne Medicines Ltd. (formerly BeiGene, Ltd.)
Reporting Period: Quarter ended June 30, 2026 (Q2 2026)
Business Overview: A global oncology company discovering and developing innovative cancer treatments. The company operates as a Swiss corporation following a continuation from the Cayman Islands in May 2025. It maintains a triple listing structure with ADSs on Nasdaq, ordinary shares on the Hong Kong Stock Exchange, and RMB shares on the Shanghai STAR Market.
Key Financial Metrics (Six Months Ended June 30, 2026)
| Metric | Amount (USD Millions) | YoY Change |
|---|---|---|
| Total Revenues | $3,218.5 | +32.3% |
| Net Product Revenue | $3,167.1 | +31.4% |
| Gross Profit | $2,876.8 | +36.8% |
| Gross Margin | 89.2% | +2.9 pts |
| Net Income | $464.4 | +385.8% |
| Diluted EPS (ADS) | $4.01 | +371.8% |
| Operating Cash Flow | $664.2 | +115.9% |
| Cash & Equivalents | $5,098.0 | N/A |
| Total Debt | $1,073.1 | N/A |
Material Changes vs. Prior Period
- Revenue Growth: Driven primarily by a 34.5% increase in BRUKINSA sales ($2.34B) and 19.2% growth in TEVIMBRA sales ($435M). In-licensed Amgen products in China also contributed to growth.
- Profitability Surge: Net income increased from $95.6M in the prior year period to $464.4M. This was fueled by revenue growth outpacing expense increases and improved operating leverage.
- Expense Increases:
- R&D: Increased 14.6% to $1.15B due to higher upfront license fees, Amgen co-development costs, and internal expansion.
- SG&A: Increased 15.2% to $1.15B, reflecting continued investment in global commercial expansion in the U.S. and Europe.
- Interest Expense: Increased 384.3% to $72.6M, primarily due to the effective interest method on the sale of future royalty liability and higher debt balances.
- Tax Expense: Income tax expense rose significantly to $107.3M (from $24.9M), largely due to a discrete net tax expense of ~$52.8M related to the settlement of a China subsidiary audit.
Guidance, Outlook, and Risks
- Recent Developments:
- Announced a $300 million expansion of the Hopewell, NJ manufacturing facility for small molecule capabilities.
- Received FDA accelerated approval for BEQALZI (sonrotoclax) for relapsed/refractory mantle cell lymphoma.
- Positive topline results from the Phase 3 MANGROVE study for BRUKINSA in mantle cell lymphoma.
- Liquidity: Management expects existing cash and operating cash flows to fund operations for at least the next 12 months. The company has $221M in unused borrowing capacity under its Facilities Agreement.
- Key Risks:
- Regulatory & Pricing: Exposure to U.S. and international pricing reforms, including potential "Most-Favored-Nation" pricing models and tariffs on pharmaceutical imports.
- Legal Proceedings: Ongoing trade secret litigation with AbbVie regarding a BTK degrader program; ANDA litigation filed against Zydus regarding BRUKINSA.
- Geopolitical: Risks associated with operations in China, including data security laws, cross-border data transfer restrictions, and potential trade tensions.
- Debt Covenants: Subject to financial covenants including minimum cash interest coverage and net leverage ratios.
Investor Verification Checklist
- Revenue Mix: Verify the sustainability of BRUKINSA growth rates in the U.S. and Europe amidst competitive pressures.
- Tax Settlement Impact: Confirm the finality of the China tax audit settlement and assess the likelihood of future discrete tax items.
- Debt Structure: Review the terms of the "Sale of Future Royalties" liability ($906M) and its impact on future cash flows versus traditional debt.
- Manufacturing Capacity: Assess the timeline and capital requirements for the Hopewell facility expansion and its impact on future supply chain resilience.
- Regulatory Exposure: Monitor the status of the AbbVie trade secret litigation and the outcome of the Zydus ANDA challenge.